FDA Approves RYZUMVI Expansion for Presbyopia, Modestly Positive but Core Gene-Therapy Thesis Unchanged

What happened

Opus Genetics announced that the FDA approved its supplemental New Drug Application for phentolamine ophthalmic solution 0.75% (RYZUMVI) to treat presbyopia, a common age-related near vision impairment, following positive Phase 3 VEGA-2 and VEGA-3 trial results. This label expansion was previously expected by end of 2026 and now removes that near-term regulatory binary, potentially increasing the market opportunity for the Viatris-commercialized product. Opus receives royalties and R&D reimbursements under its Viatris license agreement, though royalties have historically been described as smaller than reimbursements, so the direct financial impact may be limited initially. The approval does not address the core drivers of the WAIT rating: manufacturing readiness for OPGx-LCA5 pivotal dosing and cash burn discipline. Overall, this is a positive development for the partnered asset but does not fundamentally change the investment outlook.

Implication

Investors should view the presbyopia approval as a modest positive that removes a near-term catalyst, but it does not resolve the key uncertainties around LCA5 CMC timelines or cash runway. The stock may see a short-term bounce, but the master report's trim level of $4.80 remains an appropriate level to reduce exposure given the unchanged fundamentals. Conversely, at the current price near $3.01, the approval does not justify a re-rating without concrete progress on validated commercial-process supply for LCA5 or improved burn metrics. Monitor Viatris' commercialization execution and any updated royalty guidance in upcoming quarters, but do not overweight this event relative to the gene-therapy pipeline. The core thesis remains WAIT until auditable CMC milestones are achieved.

Thesis delta

The thesis was previously rated WAIT due to uncertainty around manufacturing readiness for OPGx-LCA5 and financing risk. This approval removes the presbyopia sNDA binary that was already anticipated by end of 2026, but it does not address the main value drivers. Therefore, the overall rating, conviction, and entry/trim levels remain unchanged.